Omega Healthcare Investors Inc
Q1 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +5.15%.
Did OHI Beat Earnings? Q1 2025 Results
Omega Healthcare Investors delivered a strong first quarter for 2025, with adjusted FFO of $0.75 per share beating the $0.46 consensus estimate by 64.40% and revenue of $276.79 million clearing expectations by 16.92% while growing 13.8% year over year. The outperformance was driven primarily by revenue from new investments completed throughout 2024 and into 2025, portfolio restructurings and transitions, and annual rent escalators, which together pushed net income to $112.06 million from $69.35 million a year ago. Investment activity remained a central theme, with Omega deploying $78.35 million in Q1 and following that with a $344 million acquisition of 45 care facilities in the U.K. and Jersey in April, bringing year-to-date investments to roughly $423 million. A brief payment disruption from tenant Genesis Healthcare, which missed its March rent before paying in full in April, drew attention but did not derail the quarter. Management raised full-year 2025 AFFO guidance to $2.95 to $3.01 per share, up from the prior $2.90 to $2.98 range.
- Revenue from new investments completed throughout 2024 and 2025
- 2024 portfolio restructurings and transitions
- Annual rent escalators
- Gain on assets sold of $10.1 million from sale of 27 facilities
- Increase in income from unconsolidated joint ventures
- Occupancy improvement to 81.8% with EBITDARM coverage at 1.88x
“We are pleased with our first quarter results, as we continue to grow FAD per share, while further de-levering the balance sheet. We have accretively invested approximately $423 million year-to-date through April 30th and, as a result, we are increasing our 2025 AFFO guidance to be between $2.95 and $3.01 per share from our previous guidance of between $2.90 and $2.98 per share.”
Omega Healthcare Investors CEO, on the earnings call
Forward Guidance & Outlook
Omega increased its 2025 Adjusted FFO guidance to $2.95–$3.01 per diluted share from the previous range of $2.90–$2.98 per share. The revised guidance incorporates Q1 2025 actuals and $423 million in new investments completed through April 2025. Key assumptions include quarterly G&A expense of approximately $12–$14 million, repayment of a $50 million term loan in April, repayment of a $238 million secured mortgage loan in November 2025, balance sheet cash of approximately $600 million at year-end, no material changes in market interest rates, no additional operators placed on cash-basis revenue recognition, and Genesis continuing to pay full contractual obligations. The $344 million April acquisitions are assumed funded with equity issuances. The guidance excludes additional acquisitions, asset sales, certain revenue/expense items, refinancing expenses, and additional credit loss provisions.
OHI YoY Financials
OHI Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.